Corcept Therapeutics (CORT) EBITDA Margin (2012 - 2026)
Corcept Therapeutics recorded quarterly EBITDA Margin of 30.08% in Q1 2026, down 1454.96% quarter-over-quarter from 2.22% in Q4 2025, and down 3225.0% year-over-year from 0.96% in Q1 2025.
Corcept Therapeutics' EBITDA Margin history runs 15 years deep, the most recent figure standing at 30.08% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 3225.0% year-over-year to 30.08%; the TTM figure through Mar 2026 stood at 1.07% (down 1724.0% YoY), while the FY2025 annual figure was 5.88%, down 1440.0% from the prior year.
- EBITDA Margin came in at 30.08% for Q1 2026 at Corcept Therapeutics, down from 2.22% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 31.39% in Q3 2022 to a low of 30.08% in Q1 2026.
- A 5-year average of 15.81% and a median of 21.73% in 2024 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin jumped 604 bps in 2024 and plunged 3225 bps in 2026, its largest moves.
- Corcept Therapeutics' EBITDA Margin stood at 21.83% in 2022, then grew by 7 bps to 23.39% in 2023, then tumbled by 41 bps to 13.89% in 2024, then plunged by 84 bps to 2.22% in 2025, then tumbled by 1455 bps to 30.08% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 30.08%, 2.22%, and 4.92% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.24% |
| 10 | Corcept Therapeutics | 7.26 Bn | 6.92 Bn | 162.02 Mn | -30.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.08% |
| Dec 31, 2025 | 2.22% |
| Sep 30, 2025 | 4.92% |
| Jun 30, 2025 | 13.72% |
| Mar 31, 2025 | 2.17% |
| Dec 31, 2024 | 13.89% |
| Sep 30, 2024 | 25.53% |
| Jun 30, 2024 | 21.73% |
| Mar 31, 2024 | 20.09% |
| Dec 31, 2023 | 23.39% |
| Sep 30, 2023 | 25.22% |
| Jun 30, 2023 | 25.13% |
| Mar 31, 2023 | 14.06% |
| Dec 31, 2022 | 21.83% |
| Sep 30, 2022 | 31.39% |
| Jun 30, 2022 | 30.40% |
| Mar 31, 2022 | 23.13% |
| Dec 31, 2021 | 32.09% |
| Sep 30, 2021 | 31.59% |
| Jun 30, 2021 | 28.92% |
| Mar 31, 2021 | 29.33% |
| Dec 31, 2020 | 30.13% |
| Sep 30, 2020 | 24.75% |
| Jun 30, 2020 | 32.58% |
| Mar 31, 2020 | 32.29% |
| Dec 31, 2019 | 33.37% |
| Sep 30, 2019 | 32.31% |
| Jun 30, 2019 | 28.25% |
| Mar 31, 2019 | 28.44% |
| Dec 31, 2018 | 33.05% |
| Sep 30, 2018 | 27.62% |
| Jun 30, 2018 | 29.24% |
| Mar 31, 2018 | 30.02% |
| Dec 31, 2017 | 184.44% |
| Sep 30, 2017 | 32.18% |
| Jun 30, 2017 | 35.55% |
| Mar 31, 2017 | 15.86% |
| Dec 31, 2016 | 19.31% |
| Sep 30, 2016 | 11.90% |
| Jun 30, 2016 | 4.95% |
| Mar 31, 2016 | -0.12% |
| Dec 31, 2015 | 11.03% |
| Sep 30, 2015 | 0.77% |
| Jun 30, 2015 | -9.75% |
| Mar 31, 2015 | -39.89% |
| Dec 31, 2014 | -34.14% |
| Sep 30, 2014 | -70.08% |
| Jun 30, 2014 | -112.48% |
| Mar 31, 2014 | -291.92% |
| Dec 31, 2013 | -243.74% |
| Sep 30, 2013 | -369.78% |
| Jun 30, 2013 | -570.23% |
| Mar 31, 2013 | -637.33% |
| Dec 31, 2012 | -724.76% |
| Sep 30, 2012 | -727.11% |
| Jun 30, 2012 | -867.66% |